Fine Foods & Pharmaceuticals N.T.M. S.p.A.

DB:9S5 Stock Report

Market Cap: €194.4m

Fine Foods & Pharmaceuticals N.T.M Valuation

Is 9S5 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 9S5 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 9S5 (€7.78) is trading below our estimate of fair value (€16.56)

Significantly Below Fair Value: 9S5 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 9S5?

Key metric: As 9S5 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 9S5. This is calculated by dividing 9S5's market cap by their current earnings.
What is 9S5's PE Ratio?
PE Ratio40.1x
Earnings€4.85m
Market Cap€194.39m

Price to Earnings Ratio vs Peers

How does 9S5's PE Ratio compare to its peers?

The above table shows the PE ratio for 9S5 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average63.3x
GXI Gerresheimer
22.3x21.7%€2.6b
1SXP SCHOTT Pharma KGaA
26.7x15.9%€4.0b
SRT3 Sartorius
188.8x36.4%€13.4b
PSG PharmaSGP Holding
15.4x13.9%€280.6m
9S5 Fine Foods & Pharmaceuticals N.T.M
40.1x30.7%€194.4m

Price-To-Earnings vs Peers: 9S5 is good value based on its Price-To-Earnings Ratio (40.1x) compared to the peer average (63.3x).

Price to Earnings Ratio vs Industry

How does 9S5's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
9S5 40.1xIndustry Avg. 37.4xNo. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 9S5 is expensive based on its Price-To-Earnings Ratio (40.1x) compared to the European Life Sciences industry average (37.4x).

Price to Earnings Ratio vs Fair Ratio

What is 9S5's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

9S5 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio40.1x
Fair PE Ratio15.7x

Price-To-Earnings vs Fair Ratio: 9S5 is expensive based on its Price-To-Earnings Ratio (40.1x) compared to the estimated Fair Price-To-Earnings Ratio (15.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Regeneron Pharmaceuticals

US$80.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$705.00

7D

-7.1%

1Y

-3.8%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.60

7D

-6.2%

1Y

90.0%

Merck

US$246.5b

Operates as a healthcare company worldwide.

6MK

US$93.40

7D

0.3%

1Y

-0.4%